Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Opus Genetics (IRD) Receivables (2019 - 2026)

Opus Genetics has reported Receivables over the past 10 years, most recently at $1.7 million for Q1 2026.

  • Quarterly Receivables fell 43.8% to $1.7 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $1.7 million through Mar 2026, down 43.8% year-over-year, with the annual reading at $2.0 million for FY2025, 44.01% down from the prior year.
  • Receivables was $1.7 million for Q1 2026 at Opus Genetics, down from $2.0 million in the prior quarter.
  • Over five years, Receivables peaked at $10.1 million in Q3 2023 and troughed at $135000.0 in Q2 2023.
  • The 5-year median for Receivables is $2.0 million (2024), against an average of $2.7 million.
  • The largest YoY upside for Receivables was 905.93% in 2024 against a maximum downside of 81.67% in 2024.
  • A 5-year view of Receivables shows it stood at $1.3 million in 2022, then decreased by 28.66% to $926000.0 in 2023, then soared by 284.77% to $3.6 million in 2024, then crashed by 44.01% to $2.0 million in 2025, then dropped by 13.23% to $1.7 million in 2026.
  • Per Business Quant, the three most recent readings for IRD's Receivables are $1.7 million (Q1 2026), $2.0 million (Q4 2025), and $2.9 million (Q3 2025).